Quick Answer
IGC Pharma, Inc. reported Total Revenue of $1.27 million for fiscal year 2025.
IGC Pharma, Inc. Total Revenue — Annual History
| Fiscal Year | Total Revenue | YoY Change |
|---|---|---|
| 2025 | $1.27M | -5.5% |
| 2024 | $1.34M | +47.6% |
| 2023 | $911.0K | +129.5% |
| 2022 | $397.0K | -55.8% |
| 2021 | $898.0K | -77.9% |
| 2020 | $4.07M | -20.4% |
| 2019 | $5.12M | +133.3% |
| 2018 | $2.19M | +277.9% |
| 2017 | $580.4K | -90.9% |
| 2016 | $6.37M | -17.1% |
| 2015 | $7.68M | +237.9% |
| 2014 | $2.27M | -71.7% |
| 2013 | $8.03M | +91.2% |
| 2012 | $4.20M | +3.1% |
| 2011 | $4.07M | — |
Quarterly Total Revenue
| Quarter Ending | Total Revenue | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $191.0K | -53.6% | -41.8% |
| June 30, 2025 | $328.0K | +20.6% | +27.6% |
| December 31, 2024 | $257.0K | +26.0% | -37.6% |
| September 30, 2024 | $412.0K | +41.6% | +51.5% |
| June 30, 2024 | $272.0K | -51.0% | +33.3% |
| December 31, 2023 | $204.0K | -38.6% | -29.9% |
| September 30, 2023 | $291.0K | +44.1% | -47.6% |
| June 30, 2023 | $555.0K | +161.8% | +67.2% |
- IGC Pharma, Inc. showed a decrease of -5.5% in Total Revenue compared to the prior fiscal year.
- Over the 2011–2025 period, IGC Pharma, Inc.’s total revenue has declined by 68.8% (from $4.07 million to $1.27 million).
- The most recent figure is from IGC Pharma, Inc.’s fiscal year 2024 report (Form 10-K), filed with the SEC on June 27, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: